Metabolic Brain Disease 2007-12-01

The treatment of hepatic encephalopathy.

Marsha Y Morgan, A Blei, K Grüngreiff, R Jalan, G Kircheis, G Marchesini, O Riggio, Karin Weissenborn

Index: Metab. Brain Dis. 22(3-4) , 389-405, (2007)

Full Text: HTML

Abstract

Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on open or uncontrolled trials, undertaken in very small numbers of patients. In consequence, there is ongoing discussion as to whether the classical approach to the treatment of this condition, which aims at reducing ammonia production and absorption using either non-absorbable disaccharides and/or antibiotics, should be revisited, modified or even abandoned. Pros and cons of present therapeutic strategies and possible future developments were discussed at the fourth International Hannover Conference on Hepatic Encephalopathy held in Dresden in June 2006. The content of this discussion is summarized.

Related Compounds

Related Articles:

Modulation of neural activation following treatment of hepatic encephalopathy.

2013-03-12

[Neurology 80(11) , 1041-7, (2013)]

L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.

2009-01-01

[J. Gastroenterol. Hepatol. 24(1) , 9-14, (2009)]

A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.

2010-04-01

[Liver Int. 30(4) , 574-82, (2010)]

Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.

2014-07-01

[Aliment. Pharmacol. Ther. 40(1) , 63-71, (2014)]

Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): management with L-ornithine-L-aspartate and stent reduction.

2007-03-01

[Metab. Brain Dis. 22(1) , 45-50, (2007)]

More Articles...